Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo

Nigel G. Kooreman,1,2,3,4,13 Youngkyun Kim,1,2,3,7 Patricia E. de Almeida,1,2,3 Vittavat Termglinchan,1,2,3 Sebastian Diecke,8,9,10 Ning-Yi Shao,1,2,3 Tzu-Tang Wei,1,2,3 Hyoju Yi,1,2,3,7 Devaveena Dey,1,2,3 Raman Nelakanti,1,2,3 Thomas P. Brouwer,1,2,3,4 David T. Paik,1,2,3 Idit Sagiv-Barfi,5 Arnold Han,6,11,12 Paul H.A. Quax,4 Jaap F. Hamming,4 Ronald Levy,5 Mark M. Davis,6,11,12 and Joseph C. Wu1,2,3,14 1Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA 2Stanford Cardiovascular Institute of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA 3Department of Radiology, Stanford University School of Medicine, Stanford, CA 94305, USA 4Department of Surgery, Leiden University Medical Center, Leiden 2333 ZA, the Netherlands 5Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA 6Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, CA 94305, USA 7Convergent Research Consortium for Immunologic Disease, Seoul St. Mary’s Hospital, Catholic University of Korea, Seoul 06591, Korea 8Max Delbru€ck Center for Molecular Medicine in the Helmholtz Association (MDC), Robert-Rossle Strasse 10, 13125 Berlin, Germany 9DZHK (German Centre for Cardiovascular Research), Partner Site, Berlin, Germany 10Berlin Institute of Health (BIH), Berlin, Germany 11Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA 12The Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA 94305, USA